These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30174165)

  • 1. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
    Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
    Asleh R; Clavell AL; Pereira NL; Smith B; Briasoulis A; Alnsasra H; Kremers WK; Habermann TM; Otley CC; Li X; Edwards BS; Stulak JM; Daly RC; Kushwaha SS
    J Am Coll Cardiol; 2019 Jun; 73(21):2676-2688. PubMed ID: 31146812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.
    Raichlin E; Bae JH; Khalpey Z; Edwards BS; Kremers WK; Clavell AL; Rodeheffer RJ; Frantz RP; Rihal C; Lerman A; Kushwaha SS
    Circulation; 2007 Dec; 116(23):2726-33. PubMed ID: 18025531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
    Topilsky Y; Hasin T; Raichlin E; Boilson BA; Schirger JA; Pereira NL; Edwards BS; Clavell AL; Rodeheffer RJ; Frantz RP; Maltais S; Park SJ; Daly RC; Lerman A; Kushwaha SS
    Circulation; 2012 Feb; 125(5):708-20. PubMed ID: 22207715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients.
    Asleh R; Alnsasra H; Lerman A; Briasoulis A; Pereira NL; Edwards BS; Toya T; Stulak JM; Clavell AL; Daly RC; Kushwaha SS
    Am J Transplant; 2021 Feb; 21(2):626-635. PubMed ID: 32558174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients.
    Raichlin E; Prasad A; Kremers WK; Edwards BS; Rihal CS; Lerman A; Kushwaha SS
    Eur Heart J; 2009 Jun; 30(11):1356-63. PubMed ID: 19383734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft.
    Raichlin E; Chandrasekaran K; Kremers WK; Frantz RP; Clavell AL; Pereira NL; Rodeheffer RJ; Daly RC; McGregor CG; Edwards BS; Kushwaha SS
    Transplantation; 2008 Nov; 86(10):1395-400. PubMed ID: 19034009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens.
    Ueyama H; Kuno T; Takagi H; Alvarez P; Asleh R; Briasoulis A
    Heart Fail Rev; 2022 May; 27(3):869-877. PubMed ID: 32424550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.